Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02130271 · ClinicalTrials.gov registry record
PET/MRI Imaging of Neuraxial Inflammation in Sciatica Patients
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 42
- Enrollment target
NCT02130271: Completed study, sponsored by Massachusetts General Hospital.
NCT02130271 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02130271 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the spine shows areas of inflammation using a specific type of imaging (pictures).
Primary Outcome
The presence of inflammation in the spine using the radioactive tracer \[11C\]PBR28.
Interventions
- OTHER Blood draw
- DRUG Radioactive dye
- RADIATION PET/MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-12 |
What the finished NCT02130271 record still lists
NCT02130271 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Blood draw is the first listed.
NCT02130271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02130271 about?
NCT02130271 is a clinical study titled "PET/MRI Imaging of Neuraxial Inflammation in Sciatica Patients". The purpose of this study is to see if the spine shows areas of inflammation using a specific type of imaging (pictures).
What is the current status of trial NCT02130271?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2014-04. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02130271?
The interventions under investigation include: Blood draw (OTHER), Radioactive dye (DRUG), PET/MRI (RADIATION).
Who is sponsoring clinical trial NCT02130271?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia